石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approval for drug production and registration for Choline Fenofibrate Sustained-release Capsules (135mg) from National Medical Products Administration of China, being under type 4 chemical drug and regarded as passing the consistency evaluation.

Choline Fenofibrate Sustained-release Capsule is mainly used in adults with controlled diets for lowering triglyceride levels in patients with severe hypertriglyceridemia, and for treatment of patients with primary hypercholesterolemia or mixed dyslipidemia. As compared to traditional fenofibrate, choline fenofibrate has a direct effect, a lower liver and kidney burden, can be taken without dietary restrictions and safely combined with statins drug, making it a high-end triglyceride-lowering product of next generation with clinical necessity.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 16 July 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.